Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
THE defence lawyer has condemned his own client, the father of murdered 10-year-old Sara Sharif, saying he would suffer "in the circles of hell for eternity" for his crimes against his daughter.
The statement came during closing arguments in the trial of Urfan Sharif, 42, who stands accused alongside his wife Beinash Batool, 30, and Sara's uncle Faisal Malik, 29, for the brutal murder of Sara at their Woking home in August last year. They all denied the charges.
Defence barrister Naaem Mian KC has branded his own client "a scumbag" while attempting to navigate the complex web of responsibility surrounding Sara's death. "What happened to Sara was awful, and that must be the understatement of the year. It was savage, it was brutal," Mian told the jury.
During the trial Urfan, a taxi driver, reversed his initial defence strategy of blaming his wife. On the seventh day of giving evidence, he made an admission of "full responsibility" for Sara's death, confessing to beating her with a cricket bat and metal pole - though he maintains he never intended to cause serious harm.
The court heard horrific details of Sara's injuries, which included dozens of broken bones, human bite marks, and burns from both a hot iron and boiling water. Part of her finger had been cut off with a sharp instrument, and evidence suggested she had been hooded during the abuse.
Despite these admissions, Urfan's lawyer attempted to create doubt about the final moments of Sara's life. He pointed out that only Batool was present when Sara died, telling jurors, "The only person who can say what happened on the Saturday, Sunday, Monday and Tuesday when Sara is in her arms is her."
The mystery deepened with evidence that Batool made 30 calls to family members instead of contacting emergency services when she realised something was wrong with Sara. The day before Sara's body was discovered, all three defendants fled to Pakistan, only returning later to face charges.
Batool's lawyer, Caroline Carberry KC, forcefully rejected the attempt to shift blame onto her client, describing Sharif as the only "psychopath in the courtroom" and a "comfortable liar".
She highlighted Sara's spirit, quoting teachers who remembered her as "spirited, bold and fierce", suggesting that these very qualities might have triggered Sharif's violent responses.
The prosecution painted a picture of a household where violence had become normalised.
Police found damning evidence including a bloodstained cricket bat and a rolling pin bearing Sara's DNA in the family's outhouse. Prosecutor Bill Emlyn Jones KC argued it was "inconceivable" that any one defendant could have carried out the abuse without the knowledge and complicity of the others.
The case has also raised serious questions about the role of social services and the family courts system. Sharif's own lawyer suggested these institutions shared some responsibility, noting they were aware of previous accusations against his client yet still allowed him to gain custody of Sara.
As the trial draws to a close, the jury must now grapple with multiple charges against each defendant. All three have pleaded not guilty to murder, causing or allowing the death of a child, and the alternative charge of manslaughter.
The prosecutor reminded the jury of their duty: "If you know it is happening you do something to prevent it. None of them did because they were, and are, all responsible for her death and they all are guilty of her murder."
The trial at the Old Bailey continues, with the jury expected to begin deliberations soon.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.